Key study results Key efficacy endpointsEblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile...
PALO ALTO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento...
Abivertinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly targets BTK. BTK inhibitors are a large category in...
Live moderated video webcast on Wednesday, July 12th at 11:00 AM ETOCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM...
NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the...
Oak Ridge, TN, July 05, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement...
PharmAla’s Australian Joint Venture Orders First Shipment of MDMA and Psilocybin for Commercial UseVANCOUVER, British Columbia, July 04, 2023 (GLOBE...
Company successfully executes international sale and fulfilment of 100kg order of Bulk Medical Cannabis with Lyphe AustraliaCompany also issues Deferred...
Conference Call Scheduled for July 6, 2023 at 11:00 am EASTERNDUBLIN, July 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:...
CARLSBAD, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management...
BELGRADE, Mont., July 03, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company...
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab...
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface...
- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling...
Highlights key initiatives that will drive the company’s transition towards a more sustainable businessReaffirms commitment to environmentally and socially responsible...
PRESS RELEASE - REGULATED INFORMATION 30 June 2023, 7:00 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 30 June 2023...
Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the...
The Stratys™ instrument for optical genome mapping (OGM) will enable a four-fold increase in raw data generation rate compared to...